Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma

Cancer Science

Volumn 105, Issue 11, 2014, Pages 1496-1502

  Isoda, Atsushi ^a   Kaira, Kyoichi ^b   Iwashina, Masanori ^a   Oriuchi, Noboru ^b   Tominaga, Hideyuki ^c   Nagamori, Shushi ^d   Kanai, Yoshikatsu ^d   Oyama, Tetsunari ^b   Asao, Takayuki ^b   Matsumoto, Morio ^a   Sawamura, Morio ^a  

^a Department of Digestive Organ Internal Medicine National Hospital Organization Nishigunma National Hospital   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD98; L type amino acid transporter 1; Melphalan; Multiple myeloma; Prognosis

Indexed keywords

AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; CD98 ANTIGEN;

ADULT; AGED; CANCER STAGING; CHROMOSOME ABERRATION; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD98; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84911458266     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12529     Document Type: Article

References (47)

1. Greipp PR, Katzmann JA, O'Fallon WM et al. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219-23.
2. Kapoor P, Kumar S, Fonseca R et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009; 114: 518-21.
3. Shaughnessy J, Jacobson J, Sawyer J et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003; 101: 3849-56.
4. Boccadoro M, Gavarotti P, Fossati G et al. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol 1984; 58: 689-96.
5. Lokhorst HM, Boom SE, Bast BJ et al. Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. Br J Haematol 1986; 64: 271-5.
6. Alexandrakis MG, Passam FH, Kyriakou DS et al. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 2004; 27: 8-13.
7. Gastinne T, Leleu X, Duhamel A et al. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol 2007; 79: 297-304.
8. Hose D, Rème T, Hielscher T et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011; 96: 87-95.
9. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 43-77.
10. McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994; 299: 321-34.
11. Kanai Y, Segawa H, Miyamoto K et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-32.
12. Yanagida O, Kanai Y, Chairoungdua A et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
13. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008a; 98: 742-8.
14. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-92.
15. Sakata T, Ferdous G, Tsuruta T et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 2009; 59: 7-18.
16. Ichinoe M, Mikami T, Yoshida T et al. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 2011; 61: 281-9.
17. Kaira K, Sunose Y, Arakawa K et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 2012; 107: 632-8.
18. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. Br J Haematol 2003; 121: 749-57.
19. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-54.
20. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol, 2005; 23: 3412-20.
21. Kaira K, Oriuchi N, Imai H et al. L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008b; 99: 2380-6.
22. Xu JL, Lai R, Kinoshita T et al. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55: 530-4.
23. Li R, Younes M, Frolov A et al. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res 2003; 23: 3413-8.
24. Witte D, Ali N, Carlson N et al. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 2002; 22: 2555-7.
25. Alexanian R, Bergsagel DE, Migliore PJ et al. Melphalan therapy for plasma cell myeloma. Blood 1968; 31: 1-10.
26. Kapoor P, Rajkumar SV, Dispenzieri A et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 2011; 25: 689-96.
27. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med, 2008; 359: 906-17.
28. Bergsagel DE, Bailey AJ, Langley GR et al. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743-8.
29. Cuzick J, Erskine S, Edelman D et al. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 1987; 55: 523-9.
30. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-44.
31. Kanai Y, Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J Toxicol Sci 2003; 28: 1-17.
32. Lin J, Raoof DA, Thomas DG et al. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 2004; 6: 74-84.
33. Harada N, Nagasaki A, Hata H et al. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta Haematol 2000; 103: 144-51.
34. Blosmanis R, Wright JA, Goldenberg GJ. Sensitivity to melphalan as a function of transport activity and proliferative rate in BALB/c 3T3 fibroblasts. Cancer Res 1987; 47: 1273-7.
35. Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood 2012; 120: 927-8.
36. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-30.
37. Haessler J, Shaughnessy JD Jr, Zhan F et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073-9.
38. Pineda-Roman M, Bolejack V, Arzoumanian V et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393-9.
39. Zhan F, Huang Y, Colla S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-8.
40. 11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 2010; 99: 217-25.
41. Wiriyasermkul P, Nagamori S, Tominaga H et al. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med 2012; 53: 1253-61.
42. Usmani SZ, Mitchell A, Waheed S et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 2013; 121: 1819-23.
43. Zamagni E, Patriarca F, Nanni C et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011; 118: 5989-95.
44. 18F-FDG. Ann Nucl Med 2012; 26: 811-6.
45. Kaira K, Oriuchi N, Otani Y et al. Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007; 13: 6369-78.
46. 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2013; 40: 1692-700.
47. Ghobrial IM, Weller E, Vij R et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011; 12: 263-72.